Ipilimumab shows a survival benefit in melanoma

The sentence that opened the paper

The 2010 report in the New England Journal of Medicine began by conceding the problem. An improvement in overall survival among patients with metastatic melanoma had been an elusive goal.

That was the state of play. Melanoma that had spread was a disease where nothing had been shown to help people live longer. This trial changed that, and it did so with a drug that does not attack the tumor at all.

Taking the brakes off

Ipilimumab blocks a protein called CTLA-4, short for cytotoxic T-lymphocyte-associated antigen 4. CTLA-4 sits on T cells and acts as a brake, damping down immune responses so the body does not attack itself.

Tumors benefit from that brake. Blocking it lets T cells stay switched on and go after cancer cells. This is why the drug is called a checkpoint inhibitor: it releases an immune checkpoint rather than poisoning a dividing cell.

The trade-off is written into the design. A less restrained immune system can attack healthy tissue too. Our page on immunotherapy explains how this class differs from chemotherapy.

The trial

The study enrolled 676 people with unresectable stage III or stage IV melanoma whose disease had progressed during treatment. All carried a particular tissue type, HLA-A*0201, needed for the vaccine being tested alongside.

They were assigned in a 3 to 1 to 1 ratio: 403 received ipilimumab plus a gp100 peptide vaccine, 137 received ipilimumab alone, and 136 received the vaccine alone. Ipilimumab was given by infusion every three weeks for up to four doses, at an amount based on body weight.

Median overall survival was 10.0 months with ipilimumab plus the vaccine, against 6.4 months with the vaccine alone. The hazard ratio for death was 0.68, with p below 0.001. Ipilimumab alone gave a median of 10.1 months, with a hazard ratio of 0.66 against the vaccine alone.

There was no difference between the two ipilimumab groups. The vaccine was adding nothing. The drug was doing the work.

The cost of releasing the brake

The same paper reports the harms without softening them.

Grade 3 or 4 immune-related adverse events occurred in 10 to 15 percent of people given ipilimumab, against 3 percent of those given the vaccine alone. There were 14 deaths related to the study drugs, or 2.1 percent of participants, and 7 of those were linked to immune-related events.

FDA approved ipilimumab on March 25, 2011, for unresectable or metastatic melanoma. The label carried a boxed warning about severe and fatal immune-mediated reactions, naming enterocolitis, hepatitis, dermatitis including toxic epidermal necrolysis, neuropathy, and endocrinopathy. Those words describe the immune system attacking the bowel, liver, skin, nerves, and hormone glands.

The label told doctors to assess for these signs and to check blood chemistry, including liver and thyroid function, before each dose.

Why this one is a landmark

Three and a half months of extra median survival is a modest figure. Its importance is not the size.

It was the first proof that switching the immune system back on could make people with an advanced solid tumor live longer. Everything that followed in checkpoint inhibition, including the PD-1 drugs now used across many cancers, rests on that demonstration.

Where melanoma stands

About 112,000 new melanoma cases and 8,510 deaths are projected in the United States for 2026 by the American Cancer Society, the source SEER cites for those counts. Five-year relative survival is 94.7 percent overall for people diagnosed from 2016 to 2022.

That figure is high because 77 percent of melanomas are found while still confined to the skin, where five-year relative survival is 100.0 percent. It is 76.0 percent once regional lymph nodes are involved and 34.0 percent for distant disease, which is 5 percent of cases. These are group averages and do not describe any individual. The distant-disease figure is also the one that has moved most since 2010.

When to have a spot looked at

Melanoma found early is a surgical problem, not a systemic one. That is why the checks matter.

Make an appointment if a mole changes in size, shape, or color, if a new spot appears that does not resemble your others, or if any spot bleeds, itches persistently, or becomes raised and firm. Anyone with many unusual moles, or a personal or family history of melanoma, should ask about a regular skin check rather than waiting for a change. Our guide to melanoma covers what happens after a suspicious spot is found.

What this does not mean

• The result is a median. Half the people in the ipilimumab groups lived less than 10 months.
• Everyone enrolled had already progressed on other treatment and carried a specific tissue type. The trial does not describe untreated melanoma.
• Immune-related side effects here were severe in 10 to 15 percent and fatal in a small number. That is part of the finding.
• Treatment for advanced melanoma has changed substantially since 2011. This page is history, not current guidance.

Sources

• Hodi FS, et al., N Engl J Med 2010 — abstract via NCBI E-utilities
• FDA approval letter, YERVOY (ipilimumab), March 25, 2011
• FDA prescribing information, YERVOY, 2011
• SEER Cancer Stat Facts: Melanoma of the Skin

How this page was made

An AI-assisted editorial system helped prepare this page. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown. Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.